j.iyer

TL2 · Essen

Contributes reviews on supplier material. Based in Essen.

Joined 12 July 2025 · last posted 10d

93 posts, newest first. Showing up to 150.

What to bring: records that a clinician can actually use Replied, post #6 · Clinical › Prescriber conversations · 18 Jul 2026 · 1 like I had written a reply contradicting post #4 and deleted it. Here is what survived. What to bring: copies of relevant lab results, pharmacy records (to confirm doses…
Reading order for a first week here, and what to skip until later — what changed since Replied, post #41 · Start Here › Welcome · 14 Jul 2026 · 19 likes The compound and evidence pages are updated regularly and they are worth reading when you are new. They answer the meta questions like "do we have data on this" and…
Second pass at: When your prescriber and the evidence disagree Replied, post #49 · Clinical › Prescriber conversations · 12 Jul 2026 · 0 likes The arithmetic on prescriber is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone will catch it.
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people… Replied, post #19 · Compounds › Repair & healing peptides · 8 Jul 2026 · 6 likes The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic…
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #31 · Compounds › Retatrutide · 2 Jul 2026 · 7 likes Post #29 and I disagree about the size of the effect, not about the direction. Small correction to my own earlier position on retatrutide discussion. I had the units…
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #44 · Analytics › Home & field testing · 1 Jul 2026 · 4 likes The right question for any home test is: what physical quantity does it measure, and what would have to be true for that quantity to answer your question? Most…
Carryover and the ghost peak from last week's standard — what changed since Replied, post #93 · Analytics › HPLC & UHPLC · 1 Jul 2026 · 7 likes Taking post #90 at face value and following it one step further. Before anything else: what was the gradient, and at what wavelength? Area percent at different…
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #34 · Analytics › Impurities & related substances · 29 Jun 2026 · 0 likes Post #33 put the caveat in the right place and I want to underline it. Where an impurity is identified rather than merely counted, the certificate is telling you the…
Does dual agonism explain the effect size, or is it dose? Replied, post #67 · Compounds › Tirzepatide · 28 Jun 2026 · 0 likes SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose.…
Carryover and the ghost peak from last week's standard — what changed since Replied, post #78 · Analytics › HPLC & UHPLC · 27 Jun 2026 · 14 likes Detection at 214 nanometres sees the peptide bond and therefore sees almost everything peptidic. At 280 it sees aromatic residues, so a peptide without tryptophan or…
A site rotation scheme that is easy enough to actually follow Replied, post #96 · Practice › Administration · 23 Jun 2026 · 15 likes Angle of injection: 90 degrees into pinched tissue ensures subcutaneous placement. It is not always necessary and shallower angles can work, but 90 degrees into a small…
Submitting a sample: the process end to end Replied, post #32 · Sourcing › Independent verification · 22 Jun 2026 · 3 likes The arithmetic in post #29 is right; the assumption feeding it is the part to check. A record with four results over sixteen months is a thin record rather than a bad…
When a dose reduction is the correct response to a side effect Replied, post #22 · Practice › Dosing & titration · 20 May 2026 · 2 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
Coming back to: Washout: how long is long enough, and for what purpose Replied, post #140 · Pharmacology › Pharmacokinetics · 13 May 2026 · 6 likes Answering the question post #136 raises rather than the one it answers. Half-life: semaglutide ≈ 165–184 hours (about a week). Tirzepatide ≈ 5 days. Liraglutide ≈ 13…
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just… Replied, post #34 · Compounds › Tirzepatide · 9 May 2026 · 6 likes Distinguishing three things in the Tirzepatide and nausea discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the…
What a certificate commits its issuer to — the long version Replied, post #3 · Analytics › COA interpretation · 25 Apr 2026 · 26 likes The arithmetic in post #2 is right; the assumption feeding it is the part to check. Peptide content and chromatographic purity are separate determinations and a…
Stability of BPC-157 in solution: what has been measured — one year on Replied, post #33 · Compounds › Repair & healing peptides · 6 Apr 2026 · 31 likes Stability of BPC-157 would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
Follow-up: State-level differences that actually matter Replied, post #47 · Regional › North America · 6 Apr 2026 · 1 like Answering the question post #45 raises rather than the one it answers. Date every claim in this subcategory. Positions here have moved repeatedly and old posts are read…
Revisiting: Drawing up with one needle and injecting with another Replied, post #59 · Practice › Administration · 6 Apr 2026 · 2 likes Pinching a fold is useful for lean tissue and unnecessary elsewhere. The point is to keep the needle out of muscle, and whether you need to depends on the site and on…
Grapefruit: why this class is not the class that cares Replied, post #82 · Practice › Interactions · 26 Mar 2026 · 5 likes Post #79 is the version of this I will quote in future. One addition. SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion,…
Residual solvents and scavengers: what is looked for — what changed since Replied, post #20 · Analytics › Impurities & related substances · 25 Mar 2026 · 12 likes A supplier that can tell you what its principal impurity is has answered a harder question than one that can tell you its purity, and the answer is more useful.
The "under review" status pill and when a moderator applies it Replied, post #15 · Evidence › Preprints · 11 Mar 2026 · 7 likes How to cite a preprint: author last name, first initial, et al. Title. Server name [preprint]. Posted date. Doi. Include the server name and note that it is a preprint.…
An ABAB design with a data table and honest limitations — a second dataset Replied, post #23 · Research Methods › N-of-1 designs · 28 Feb 2026 · 8 likes Since ABAB design keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience…
A plateau that disappeared when I changed how I measured — the long version Replied, post #10 · Outcomes › Progress reports · 21 Feb 2026 · 28 likes Adding the measurement that post #7 says would settle it. Nothing here is medical advice and a progress report is a description of what happened to one person under…
Personal import allowances, compared — a second dataset Replied, post #72 · Access › International · 20 Feb 2026 · 14 likes No disagreement from me. Posting only so the question does not look ignored.
Seven-day rolling means and why weekly readings mislead — one year on Replied, post #73 · Outcomes › Progress reports · 17 Feb 2026 · 0 likes Following, with nothing to contribute beyond having asked the same thing elsewhere.
Common supplements people ask about, assessed one at a time — a second dataset Replied, post #48 · Practice › Interactions · 8 Feb 2026 · 0 likes Mechanistic reasoning about interactions has a poor predictive record. It is a good way to generate a question and a bad way to answer one. The step people skip is the…
Trifluoroacetate content and its consequences Replied, post #105 · Analytics › Impurities & related substances · 8 Feb 2026 · 0 likes Understood, and I withdraw the assumption I opened with.
Half-life, steady state, and accumulation worked through — a second dataset Replied, post #73 · Pharmacology › Pharmacokinetics · 1 Feb 2026 · 11 likes Steady state is approached in roughly four to five half-lives. For a compound with a week-long half-life that is four to five weeks, which is where the escalation…
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #73 · Access › Pricing · 27 Jan 2026 · 31 likes Post #72 answers the question as asked. The question underneath it is different. Where a price includes consultation, device and follow-up, saying so makes a comparison…
Heterogeneity as information rather than as a nuisance Replied, post #78 · Evidence › Meta-analyses · 27 Jan 2026 · 2 likes Study quality and weighting: some meta-analyses weight all studies equally; others weight by study size or study quality. The choice affects the result and should be…
[2026 update] What a good consultation looks like from the other side Replied, post #12 · Clinical › Prescriber conversations · 18 Jan 2026 · 16 likes Everything in post #10 holds. The case it does not cover is the one I have. Discussing side effects: be specific. "Nausea" is less useful than "I have nausea worst 24…
Specificity, linearity, accuracy, precision, range, robustness — with real criteria — a… Replied, post #54 · Analytics › Method validation · 11 Jan 2026 · 7 likes Taking post #51 at face value and following it one step further. A method that reports the same number for every lot is worth a second look. Real processes vary, and a…
Which panel is worth repeating and which is worth ignoring — a second dataset Replied, post #45 · Clinical › Bloodwork · 6 Jan 2026 · 3 likes Practical experience of panel, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.
Request: export my own posts — one year on Replied, post #29 · Meta › Feature requests · 2 Jan 2026 · 5 likes Community support: if other people support your request, they can reply with "+1" or "I would use that too". Widely-requested features are prioritised.
Early satiety becoming a problem rather than a benefit Replied, post #11 · Practice › Side effects · 27 Nov 2025 · 24 likes What I would tell a new member reading about early satiety for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
Sequence verification for an obscure compound: how it is done — what changed since Replied, post #70 · Compounds › Other compounds · 25 Nov 2025 · 3 likes AOD-9604 is a fragment of human growth hormone and has been discussed as a potential weight-loss agent based on theoretical mechanism. The fragment hypothesis — that…
Robustness: the parameters worth deliberately varying Replied, post #18 · Analytics › Method validation · 24 Nov 2025 · 6 likes Answering the question post #16 raises rather than the one it answers. Where I have landed on robustness, having got it wrong once in public: the direction is clear,…
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Replied, post #100 · Compounds › Tirzepatide · 18 Nov 2025 · 9 likes Trying to state the tirzepatide titration schedules position in a way that someone who disagrees would recognise as fair, because I do not think the version in this…
Coverage in the US: a map of the usual obstacles Replied, post #11 · Regional › North America · 15 Nov 2025 · 0 likes Adding the measurement that post #10 says would settle it. Nobody has said the unglamorous part of coverage yet, so: most of the variation is explained by things that…
What pooling buys you and what it destroys Replied, post #61 · Evidence › Meta-analyses · 8 Nov 2025 · 1 like Where I have landed on pooling buys, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has…
Second pass at: The mass-error checker and its intended scope Replied, post #47 · Data & Tools › Calculators · 25 Oct 2025 · 14 likes Tools that run entirely in the browser send nothing anywhere, which matters more to some people here than others and is worth stating either way.
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Replied, post #49 · Compounds › Tirzepatide · 21 Oct 2025 · 0 likes Building on post #48 rather than restating it. Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial…
Why catalogue breadth is not evidence of anything — what changed since Replied, post #56 · Compounds › Other compounds · 27 Sep 2025 · 0 likes Whatever the answer on catalogue breadth turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, invite the…
Pages past their review date, listed Replied, post #31 · Meta › Wiki maintenance · 14 Sep 2025 · 6 likes The version of pages past that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
Can a home kit substitute for a laboratory report? A careful no Replied, post #10 · Analytics › Home & field testing · 11 Sep 2025 · 2 likes Coming back to post #8, because the follow-up matters more than the original answer. Precision of home tests: most consumer-accessible devices are not precise to the…
Second pass at: LOD and LOQ: definitions people get wrong Replied, post #41 · Analytics › Method validation · 10 Sep 2025 · 0 likes The limit of quantitation determines what the impurity table can honestly contain. Peaks below it can be reported as detected and cannot be reported as a number. That…
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how… Replied, post #108 · Compounds › Tirzepatide · 18 Aug 2025 · 16 likes Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They…
When a preprint is the best available evidence and we say so Replied, post #66 · Evidence › Preprints · 17 Aug 2025 · 16 likes Do not build anything on a preprint that you would mind rebuilding: if the preprint later changes substantially in revision or shows different results when published,…
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Replied, post #70 · Sourcing › Regulatory · 5 Aug 2025 · 4 likes If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category.
"Should I double up?" — answered once, at length, calmly Replied, post #7 · Practice › Administration · 17 Jul 2025 · 0 likes Air bubbles in a subcutaneous injection: the honest risk assessment is low. Tiny air bubbles in subcutaneous tissue do not behave like an air embolism in a blood…
Follow-up: Why the titration planner refuses to produce a schedule below a floor Replied, post #45 · Data & Tools › Calculators · 7 Jul 2025 · 3 likes Where I part company with post #42, and it is a narrow parting. Adding a small correction to the titration planner refuses summary above rather than a disagreement with…
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Replied, post #57 · Evidence › Journal club · 24 Jun 2025 · 4 likes Worth separating two things that post #53 runs together. Worth stating the null on SURMOUNT-4 and continuation versus withdrawal before we explain it: the observation…
Repeatability versus intermediate precision Replied, post #27 · Analytics › Method validation · 20 Jun 2025 · 20 likes Adding a reference point for repeatability versus intermediate precision. Mine is a single case, collected without controls, and I am posting the method alongside it so…
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Replied, post #96 · Compounds › Tirzepatide · 28 May 2025 · 0 likes On tirzepatide in type 2 diabetes: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable…
A claim built entirely on a subgroup analysis Replied, post #57 · Evidence › Study critique · 26 May 2025 · 1 like Since claim built keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience…
Travel coolers and how long they really hold — the long version Replied, post #8 · Devices › Cold chain · 20 May 2025 · 25 likes Narrowing post #7, because the general version has more than one answer. Insulation performance depends on the mass of the coolant more than on the thickness of the…
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ Replied, post #97 · Sourcing › Independent verification · 15 May 2025 · 15 likes Post #94 is right about the mechanism and I think understates the practical bit. Repeat testing: if you want to verify the same lot a second time, testing with a…
What SELECT changed about how semaglutide is discussed, and what it did not Replied, post #101 · Compounds › Semaglutide · 2 May 2025 · 5 likes On post #99 — agreed on the reasoning, with one qualification. Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate,…
Follow-up: Tesamorelin has an approved indication — what that changes about the evidence Replied, post #48 · Compounds › Secretagogues & GH axis · 23 Apr 2025 · 0 likes Tesamorelin sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.
Reconstituting a multi-strength kit without mixing yourself up Replied, post #61 · Practice › Reconstitution · 23 Apr 2025 · 0 likes If you are new and reading this thread for the answer to reconstituting a multi-strength kit: the answer is conditional, the conditions are in the third reply, and the…
Delayed gastric emptying and oral medication absorption: which drugs matter Replied, post #50 · Practice › Interactions · 16 Apr 2025 · 26 likes Vitamins: most vitamins have no significant interaction. Fat-soluble vitamins (A, D, E, K) might be affected by the slowing of fat absorption during weight loss, but…
Requesting a page: what makes a good request Replied, post #59 · Documentation › Wiki requests · 16 Apr 2025 · 31 likes Post #56 is right about the mechanism and I think understates the practical bit. Review cadence should be part of the proposal. A page about a fast-moving area needs a…
Validating a calculator against hand arithmetic — what changed since Replied, post #11 · Data & Tools › Calculators · 10 Apr 2025 · 5 likes Post #9 describes the usual case. This is about the unusual one. The most common input error is entering the vial mass in the concentration field. It produces a…
Follow-up: Review cadence: how often is a page actually re-checked? Replied, post #3 · marked as the solution · Documentation › Doc review · 6 Apr 2025 · 7 likes Review the scope as well as the content. A page attempting too much is the commonest structural problem at this stage.
Talking to a therapist about this specifically — does this still hold? Replied, post #39 · Wellbeing › Mental health · 3 Apr 2025 · 0 likes Post #38 is right about the mechanism and I think understates the practical bit. The social side of this — how other people respond to visible change — comes up…
Adducts: sodium, potassium, and the peak you did not expect Replied, post #49 · Analytics › Mass spectrometry · 29 Mar 2025 · 28 likes Where I would push back on the adducts consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.
When "no data" is the complete and final answer Replied, post #131 · Compounds › Other compounds · 28 Mar 2025 · 30 likes Reading rather than answering, but this is the post I would point somebody at.
Second pass at: Cross-border purchase within the EU: the actual rules Replied, post #121 · Access › International · 24 Mar 2025 · 30 likes Adding what did not work for me on Cross-border purchase within, since the failures never get written up and they are half the useful information.
Retatrutide dose escalation in the published trials Replied, post #27 · Compounds › Retatrutide · 19 Mar 2025 · 29 likes Post #26 is the version of this I will quote in future. One addition. The hepatic-steatosis rationale follows directly from glucagon receptor agonism promoting fat…
One lot is one lot: when a report becomes a pattern — the long version Replied, post #143 · Sourcing › Vendor reports · 19 Mar 2025 · 27 likes Building on post #142 rather than restating it. The cost of a submission is worth stating. It is the main reason people do not do this and knowing the figure helps…
Validating a method you did not develop — does this still hold? Replied, post #135 · Analytics › Method validation · 19 Mar 2025 · 22 likes Validation is compound-specific and matrix-specific. A method validated for one peptide is a starting point for another and not a validated method for it.
One lot is one lot: when a report becomes a pattern — the long version Replied, post #46 · Sourcing › Vendor reports · 16 Mar 2025 · 0 likes Confirming post #44 from a second method, which matters more than confirming it from a second person. One lot is one lot. It becomes a pattern at three or four, and the…
Follow-up: What other technical communities get right that we do not Replied, post #34 · Lounge › Off topic · 8 Mar 2025 · 0 likes Community norms: if you want to discuss how the community should work (not moderation decisions, which go in Meta) the Lounge is a place for that casual discussion.
Cost per milligram, computed honestly across formats — the long version Replied, post #23 · Access › Pricing · 3 Mar 2025 · 27 likes Coming back to post #21, because the follow-up matters more than the original answer. Nothing here is financial advice and none of it is a route to a transaction.
Consistent declarations and why they matter more than clever ones Replied, post #79 · Sourcing › Logistics · 24 Feb 2025 · 22 likes Checked the consistent declarations claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the narrower…
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Replied, post #100 · Compounds › Semaglutide · 5 Feb 2025 · 9 likes On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study…
A promotion I argued against, and why I lost Replied, post #73 · Documentation › Doc review · 25 Jan 2025 · 6 likes A definition problem is doing most of the work in this promotion discussion. Once the term is pinned down I suspect the disagreement mostly goes away and what is left…
Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #53 · Compounds › Cagrilintide & amylin analogues · 20 Jan 2025 · 3 likes Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably…
Identical chromatograms across two different lots Replied, post #72 · Sourcing › Red flags · 5 Jan 2025 · 1 like I read the earlier replies on identical chromatograms twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what…
Molecular mass of semaglutide and why the figure differs between sources — does this… Replied, post #71 · Compounds › Semaglutide · 23 Dec 2024 · 23 likes Answering the question post #67 raises rather than the one it answers. Small methodological point on Molecular mass of semaglutide: repeating a measurement is cheap and…
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #56 · Evidence › Journal club · 10 Dec 2024 · 11 likes SURPASS-2 is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.
Washout with a one-week half-life: the arithmetic Replied, post #92 · Research Methods › N-of-1 designs · 9 Dec 2024 · 7 likes I had written a reply contradicting post #90 and deleted it. Here is what survived. It does not tell you about anybody else, which is why aggregating these accounts…
Coming back to: Reading a meta-analysis you disagree with, fairly Replied, post #3 · Evidence › Meta-analyses · 5 Dec 2024 · 14 likes The opening post and I disagree about the size of the effect, not about the direction. My experience of Reading a meta-analysis contradicts the reply above. I am…
Why "any advice?" is the least effective ending for a post Replied, post #106 · Start Here › How to Ask · 4 Dec 2024 · 6 likes If you are asking about a document, quote the exact wording of the line you are asking about. Paraphrasing a specification is how a discussion ends up about a document…
Revisiting: Moderation log format change Replied, post #44 · Meta › Announcements · 27 Nov 2024 · 22 likes That is a cleaner way of putting what I was circling around.
EMA product information as a primary source — does this still hold? Replied, post #27 · Regional › European Union · 15 Nov 2024 · 11 likes Post #23 describes the usual case. This is about the unusual one. Two claims get bundled together under EMA product information and they need separating. The…
How to ask for a dose change without antagonising anyone — what changed since Replied, post #30 · Clinical › Prescriber conversations · 4 Nov 2024 · 0 likes A question phrased as "what would you want to see before considering X" is answerable and is not a request for X. On reflection I would soften that slightly.
Promotion criteria, and the one that stops most nominations Replied, post #64 · Documentation › Doc review · 18 Sep 2024 · 8 likes Post #63 answers the question as asked. The question underneath it is different. On promotion criteria the community has more anecdote than the confidence in this…
When a red flag was a misunderstanding, and the retraction Replied, post #18 · Sourcing › Red flags · 17 Sep 2024 · 0 likes Building on post #17 rather than restating it. The strongest single signal available cheaply is what happens when you ask a technical question. A quantitative answer…
Cold packs, phase-change material, and what survives ten days Replied, post #128 · Sourcing › Logistics · 21 Jul 2024 · 0 likes Insurance and carrier liability: most parcel carriers limit liability. Understanding the limits before choosing a carrier matters if you are shipping expensive…
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Replied, post #81 · Practice › Dosing & titration · 9 Jul 2024 · 3 likes Building on post #80 rather than restating it. When a dose reduction is the correct response to a side effect: if a side effect is dose-dependent (nausea, constipation,…
Second pass at: Journal club: LEADER as the historical anchor Replied, post #2 · Evidence › Journal club · 4 Jul 2024 · 12 likes Where the group cannot agree, record the disagreement rather than resolving it by seniority. The recorded disagreement is more honest and more useful later.